Showing results (1641-1650 of 1,735) with videos related to
Sort By:
Pageof 174
Blood|May 5, 2018
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, et al.Plos One|August 4, 2023
Amygdalar activity measured using FDG-PET/CT at head and neck cancer staging independently predicts survivalMalek Z O Hassan, Ahmed Tawakol, Ying Wang, et al.Nature Medicine|May 3, 2016
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteinsStanley Chun-Wei Lee, Heidi Dvinge, Eunhee Kim, et al.Cancer Cell|July 12, 2011
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitorScott R Daigle, Edward J Olhava, Carly A Therkelsen, et al.Scientific Reports|January 21, 2017
Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3aJennifer R Deuis, Zoltan Dekan, Joshua S Wingerd, et al.Nature Cell Biology|August 17, 2023
KDM6A epigenetically regulates subtype plasticity in small cell lung cancerLeslie Duplaquet, Yixiang Li, Matthew A Booker, et al.Cancer Research|March 31, 2025
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative EffectNancy Klemm, Roman R Schimmer, Nils K Konrad, et al.Nature|March 16, 2023
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaGhayas C Issa, Ibrahim Aldoss, John DiPersio, et al.Blood Advances|May 5, 2026
Combining Menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemiaNastassja Keora Scheidegger, Constanze Schneider, Gabriela Alexe, et al.Nature Communications|May 8, 2026
CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trialsWallace Bourgeois, Hannah E Rice, Daniela V Wenge, et al.Pageof 174